Key result
This review discusses the diagnostic work-up and cardiotoxic risk of anthracyclines and trastuzumab, highlighting cardiotoxicity as a risk factor in multimodal breast cancer therapy.
Why the study?
What are the adverse cardiovascular effects and diagnostic work-up for cardiotoxicity induced by systemic anticancer treatments like anthracyclines and trastuzumab in cancer patients?
What are the adverse cardiovascular effects and diagnostic work-up for cardiotoxicity induced by systemic anticancer treatments like anthracyclines and trastuzumab in cancer patients?
This review highlights the importance of monitoring and managing the cardiotoxic risks associated with common anticancer therapies like anthracyclines and trastuzumab, especially in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Supports cardiac monitoring in anthracycline- or trastuzumab-treated breast cancer patients; leaves optimal diagnostic strategies open.
Geiger et al. (2010) conducted a review in Cancer (including breast cancer). Anticancer therapy (anthracyclines and trastuzumab) was evaluated. This review discusses the diagnostic work-up and cardiotoxic risk of anthracyclines and trastuzumab, highlighting cardiotoxicity as a risk factor in multimodal breast cancer therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: